|
Market Closed -
Nasdaq
16:00:00 2026-11-13 EST
|
5-day change | 1st Jan Change | ||
| 4.440 USD | +6.22% |
|
+6.47% | -52.03% |
| 10-21 | Lexaria Bioscience Corp. Reaches Full Enrollment and Continues Dosing on Schedule with Human Pilot Study #7 | CI |
| 10-15 | Lexaria Bioscience Corp. Announces Results from Animal Study Glp-1-A26-1 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| LEXARIA BIOSCIENCE CORP. | Other Pharmaceuticals | +6.22% | +6.47% | -52.03% | -74.04% | -95.49% | 8.81M |  |  | |
- Stock Market
- Stocks
- LEXX Stock
- Charts Lexaria Bioscience Corp.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
